NEW MJ NEWS

AbbVie to Host First-Quarter 2021 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its first-quarter 2021 financial results on Friday, April 30, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

View original content:http://www.prnewswire.com/news-releases/abbvie-to-host-first-quarter-2021-earnings-conference-call-301258997.html

SOURCE AbbVie


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

TerrAscend Corp. (TSNDF) Reaches Four Dispensary Cap in Maryland with Closing of Herbiculture Acquisition

TerrAscend Reaches Four Dispensary Cap in Maryland with Closing of Herbiculture Acquisition…

$PZOO to Operate New Lab in Colorado Cannabis Testing Market

Pazoo Wholly-Owned Subsidiary Harris Lee Announces Agreement in Principal with Harris Lee…

$PMCB Releases Industry Report

Chardan Releases Industry Report Covering PharmaCyte Biotech PharmaCyte Biotech, Inc. (PMCB), a…

AbbVie Inc. (ABBV) to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society®

AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022…